Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s biologics facility in Bloomington, Indiana.

As part of the agreement, Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million doses of the vaccine candidate intended to supply the U.S. market starting in the third quarter of 2020.

The companies are in discussions to secure fill-finish capacity for continued production of hundreds of millions of additional doses.

Catalent will also provide clinical supply services from its facilities in Philadelphia, Pennsylvania, including packaging and labelling, as well as storage and distribution to support Moderna’s Phase 3 clinical study for this candidate.

John Chiminski, Chair and Chief Executive Officer of Catalent. “Catalent’s proven expertise in manufacturing scale-up and commercial production are well suited to support Moderna’s efforts to prepare for wide-scale supply of this vaccine candidate so that it is available if appropriate to address the pandemic.”

Catalent’s state-of-the-art 875,000 square-foot biologics facility in Bloomington will undertake this vial filling work under barrier isolator technology.

Moderna will leverage the site’s recent packaging expansion, which provides fully automated and high-speed packaging capabilities to accelerate manufacturing timelines.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Related news

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...